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Abstract
Background: The megencephaly mouse, mceph/mceph, is epileptic and displays a dramatically
increased brain volume and neuronal count. The responsible mutation was recently revealed to be
an eleven base pair deletion, leading to a frame shift, in the gene encoding the potassium channel
Kv1.1. The predicted MCEPH protein is truncated at amino acid 230 out of 495. Truncated
proteins are usually not expressed since nonsense mRNAs are most often degraded. However,
high Kv1.1 mRNA levels in mceph/mceph brain indicated that it escaped this control mechanism.
Therefore, we hypothesized that the truncated Kv1.1 would be expressed and dysregulate other
Kv1 subunits in the mceph/mceph mice.
Results: We found that the MCEPH protein is expressed in the brain of mceph/mceph mice.
MCEPH was found to lack mature (Golgi) glycosylation, but to be core glycosylated and trapped in
the endoplasmic reticulum (ER). Interactions between MCEPH and other Kv1 subunits were
studied in cell culture, Xenopus oocytes and the brain. MCEPH can form tetramers with Kv1.1 in
cell culture and has a dominant negative effect on Kv1.2 and Kv1.3 currents in oocytes. However,
it does not retain Kv1.2 in the ER of neurons.
Conclusion: The megencephaly mice express a truncated Kv1.1 in the brain, and constitute a
unique tool to study Kv1.1 trafficking relevant for understanding epilepsy, ataxia and pathologic
brain overgrowth.
Background
The megencephaly mice (BALB/cByJ-Kv1.1mceph/mceph, here
denoted mceph/mceph) [1] have an 11 base pair deletion in
the Shaker-like voltage-gated potassium channel subunit
Kv1.1  [2]. This mutation causes progressive postnatal
complex partial seizures and a unique pathologic brain
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overgrowth [2]. The enlargement is not uniform but
restricted to the hippocampus and ventral cortex, with
28% and 72% larger area compared to wildtype at 12
weeks of age [3]. The enlargement is in part due to that the
numbers of both neurons and glia cells are dramatically
increased in the hippocampus which is caused by
increased proliferation and/or reduced apoptosis (Alm-
gren et al, unpublished).
Immunoblot using the Kv1.1 N-terminal antibody on brain lysate from wild type, Kv1.1-null and mceph/mceph Figure 1
Immunoblot using the Kv1.1 N-terminal antibody on brain lysate from wild type, Kv1.1-null and mceph/mceph. 
A. Lysate from wild type (+/+), Kv1.1 null (-/-) and mceph/mceph (m/m) brains were loaded on SDS-PAGE and immunoblotted 
with the polyclonal Kv1.1 N-terminal antibody. In wild type lysate a strong band was detected at 86 kDa, corresponding to 
Kv1.1. The same band was seen in the Kv1.1 null and mceph/mceph lysates but at a lower intensity. The 86 kDa bands in Kv1.1 
null and mceph/mceph lysates are due to antibody cross reactivity since neither Kv1.1 null nor mceph/mceph mice have any full-
length Kv1.1 protein. B. The polyclonal Kv1.1 N-terminal antibody was preincubated with the peptide used for immunization. 
Lysate from wild type (+/+) and mceph/mceph (m/m) brains were loaded on SDS-PAGE and immunoblotted with the Kv1.1 N-
terminal antibody without or after preincubation. The preincubation completely blocked the signal. C. A longer exposure of 
the immunoblot in panel A. In mceph/mceph brain lysate there was a unique band at approximately 30 kDa, which corresponds 
to the calculated weight of MCEPH (arrow).BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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The 11 base pair deletion in Kv1.1 leads to a frame shift
and a premature stop codon. The predicted truncated
Kv1.1 protein (MCEPH) will retain only the N-terminal
(T1) domain, the first transmembrane domain (S1) and
the first extracellular loop. Voltage gated potassium chan-
nels form a diverse group of membrane proteins, regulat-
ing membrane potential, neuronal excitability and nerve
signaling [4]. The channels are hetero- or homotetramers,
formed by a great variety of subunits, classified in 12 sub-
families [5]. Kv1.1 belongs to the Kv1 subfamily, consist-
ing of eight members (Kv1.1 to Kv1.8). Kv1.1, Kv1.2 and
Kv1.4 are the most abundant Kv1 subunits expressed in
the brain [6]. Although the heteromeric structure means
that a very large number of K channels can be formed in
theory [7,8], the composition of the heteromultimers in
the mammalian brain seems to be precisely regulated
[9,10]. A direct link between potassium channel dysfunc-
tion and apoptosis is that reduced intracellular potassium
levels appear to promote critical events early in the suicide
program. Treatment with potassium channel blockers
have been shown to block apoptosis in various cell types
[11]. However, neither Kv1.1 mutations, the Kv1.1 null
mouse [12] nor other epileptic models have previously
been associated with pathologic brain overgrowth. There-
fore, we hypothesized that the truncated Kv1.1 would be
expressed and dysregulate other Kv1 subunits in the
mceph/mceph mice.
Truncated proteins are usually not expressed. This is
because mRNAs with a premature stop codon are
degraded through nonsense-mediated mRNA decay
(NMD) [13]. One exception to this is genes with no
introns such as the Kv1 genes [14]. In mceph/mceph mice in
situ hybridization have shown that there is no decay but
instead an increased expression of Kv1.1 mRNA in the
hippocampus, cortex and ventral cortex [2]. Thus, it is
possible that MCEPH is expressed.
In humans Kv1.1 point mutations are reported in patients
with the autosomal dominant disorder episodic ataxia
type1 (EA1), [15]. Most are missense mutations but there
is one report of a premature stop codon, resulting in a
Kv1.1 protein that is truncated in the C-terminal
(Kv1.1∆C79). The patient carrying this mutation suffers
from a drug resistant form of EA1 [16].
Truncated Kv1.1 channels have previously been studied in
cell culture and Xenopus oocytes. When the Kv1.1∆C79
protein is expressed in cell culture it is trapped in the
endoplasmic reticulum (ER) and degraded [17]. However,
full length Kv1.1 in cell culture is also retained in the ER
[18,19]. Another experimental Kv1.1 protein truncated in
the extracellular loop between S1 and S2 is able to assem-
ble with full length Kv1.5 subunits in cell culture and the
resulting complexes are trapped in the ER [20]. In Xenopus
oocytes both the N- and C-terminal truncated Kv1.1 vari-
ants have a dominant negative effect on currents when
coinjected with full length Kv1.1 and Kv1.2 [21,22].
Knowing if the MCEPH protein is expressed and how it
interacts with other Kv1 subunits would provide further
understanding of Kv1 trafficking and clues to the down-
stream effects seen in the mceph/mceph mice.
In this paper we show that a truncated Kv1.1 protein,
MCEPH is expressed in the brain of the megencephaly
mouse. The truncated protein is trapped in the ER and
does not reach the plasma membrane of neurons. MCEPH
has the ability to form multimers with Kv1.1. It has a
dominant negative effect on Kv1.2 and Kv1.3 currents in
Xenopus oocytes, but in the brain it does not appear to
retain Kv1.2 in the ER.
Results
Antibody characterization
A polyclonal antiserum was produced by immunization
of rabbits with a synthetic peptide corresponding to
amino acids 4 to 27 of Kv1.1. The N-terminal epitope was
necessary to be able to detect the truncated MCEPH pro-
tein. Western blot on brain lysate from wild type mice
using the antiserum showed a strong band at 86 kDa but
also several weaker bands. The 86 kDa band had the same
size as that detected by the previously characterized mon-
oclonal antibody against a C-terminal epitope of Kv1.1
[23]. Preimmune serum did not recognize the 86 kDa
band but showed the same weaker bands as the antise-
rum. The antiserum was affinity purified against the pep-
tide used for immunization which reduced the number of
unspecific bands significantly (Figure 1 panel A). Preincu-
bation of the affinity purified antibody with the peptide
used for immunization absorbed the signal (Figure 1
panel B). The purified Kv1.1 N-terminal antibody was
used for all further experiments.
In immunblotting of lysate from Kv1.1 null mice an 86
kDa band was present but at a lower intensity than in wild
type (Figure 1, panel A). Since the null mouse does not
have any Kv1.1 protein this means that the antibody cross
reacts with another protein. Kv1 subunits have a high
degree of similarity so it is likely that the antibody recog-
nizes another Kv1 subunit. The peptide used for immuni-
zation share a stretch of six amino acids with Kv1.2. Both
Kv1.1 and Kv1.2 are expressed in the brain as mature glyc-
oproteins that are reported to be 86 and 88 kDa, respec-
tively [23]. The shared amino acids and the size of the
band makes Kv1.2 the likely candidate for the cross reac-
tivity.
Acetone post fixed wild type and Kv1.1-null brains were
used for immunohistochemistry. In wild type the staining
resembled Kv1.1 but the background was high. The pat-BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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tern in Kv1.1 null brain was very similar to wild type, indi-
cating cross reactivity (data not shown).
Immunohistochemistry on formalin fixed wild type brain
sections showed the same staining pattern that previously
has been reported for Kv1.1 [2]. In the hippocampus the
immunoreactivity was mainly localized in the fiber net-
works in the middle part of the molecular layer, in the
hilus and the pyramidal cell layer of CA3 (Figure 2, panel
A). When formalin fixed tissue was used the pattern in
Kv1.1 null was changed and clearly distinguishable from
wild type (Figure 2, panel B).
The conclusion is that the antibody recognizes Kv1.1. It is
cross reactive when used for immunoblotting but this is
Kv1.1 immunohistochemistry in wild type, Kv1.1-null and mceph/mceph hippocampus Figure 2
Kv1.1 immunohistochemistry in wild type, Kv1.1-null and mceph/mceph hippocampus. Immunohistochemistry on 
formalin fixed brain sections. Exposure parameters were adjusted to obtain a strong and clear signal. Note exposure times 
given to relate between panels A. Wild type hippocampus showed the same staining pattern as that previously reported for 
Kv1.1 [2] (exposure 1100 ms) B. Kv1.1 null mouse hippocampus: some cross reactivity of the antibody was seen. (exposure 
2700 ms) C. In the mceph/mceph hippocampus the immunoreactivity surrounded the nuclei of neurons especially in the dentate 
gyrus hilus (h) (exposure 2500 ms) D. Parietal neocortex in mceph/mceph (left) and wild type (right) brain: the staining of fibers 
in wild type was absent in mceph/mceph. Scale bar 200 µm; h, dentate gyrus hilus; Gr, dentate gyrus granular cell layer; wt, wild 
type; -/-, Kv1.1-null; m/m, mceph/mcephBMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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greatly reduced when used for immunohistochemistry on
formalin fixed tissue.
MCEPH expression in the brain
The 11 bp deletion in Kv1.1 in mceph/mceph mice leads to
a premature stop codon. The predicted truncated protein,
MCEPH, has a calculated weight of 27 kDa. To determine
if MCEPH is expressed in the brain the polyclonal Kv1.1
N-terminal antibody was used for immunoblotting and
immunohistochemistry. Immunoblotting showed a band
at approximately 30 kDa in brain lysate from mceph/mceph
mice (Figure 1, panel C). The intensity of the band was
much lower than that of the Kv1.1 protein in wild type
mice suggesting a low expression of the truncated protein.
The mceph/mceph mice do not have any full length Kv1.1
but, like the Kv1.1 null mice, they have the 86 kDa cross
reactivity-caused band. However, the 30 kDa band was
only present in mceph/mceph mice. No other band specific
for mceph/mceph was detected.
Immunohistochemistry was performed on formalin fixed
mceph/mceph mice brain sections. Interestingly, in mceph/
mceph there was staining only around the nuclei of cells,
and no staining in fibers (Figure 2, panel C and D). There
was some background staining resembling that of the
Kv1.1 null mouse but the overall pattern was significantly
different. The main areas with MCEPH immunoreactivity
were the hippocampus and ventral cortex. In the other
areas examined there were only a few stained cell bodies.
In the hippocampus MCEPH was expressed in neurons in
the dentate gyrus, CA1 and in CA3. This pattern is in
agreement with the previously reported mRNA expression
[2]. Taken together, the immunoblotting and immuno-
histochemistry results show that MCEPH is expressed in
the brain of the megencephaly mouse.
Trafficking of MCEPH
Kv1.1 has a single N-glycosylation site on the extracellular
loop between S1 and S2 and is expressed on the plasma
membrane as a mature glycoprotein. This glycosylation
site is preserved in MCEPH which makes it possible to
study the trafficking of MCEPH by analyzing its glycosyla-
tion pattern. Glycosylation starts in the ER where a high
mannose carbohydrate is transferred to an asparagine res-
idue. This carbohydrate can be cleaved off by the glycosi-
dases EndoH and PNGaseF. Next, the protein is
transported to the Golgi where the carbohydrate is modi-
fied and becomes resistant to EndoH but not to PNGaseF.
This is used as a marker for ER to Golgi transport.
To investigate the glycosylation status, brain lysates from
wild type and mceph/mceph  mice were treated with the
enzymes EndoH and PNGaseF and analyzed with immu-
noblotting. For Kv1.1 in wild type mice EndoH did not
affect the size of the 86 kDa band but PNGaseF reduced it
with approximately 20 kDa. This is in agreement with
other studies that have shown that the 86 kDa band is the
mature glycosylated form of Kv1.1 expressed in the
plasma membrane [18]. Both EndoH and PNGaseF
reduced the apparent molecular weight of MCEPH with
approximately 3 kDa (Figure 3). This strongly indicates
that MCEPH is core glycosylated in the ER but not trans-
ported to the Golgi. Neither mature nor unglycosylated
MCEPH was detected in the brain.
Interactions of MCEPH
Kv1 channels are tetramers and the assembly of the Kv1
subunits takes place in the ER [24]. MCEPH contains the
N-terminal tetramerization domain and might thus bind
other Kv1 subunits.
Interactions with Kv1.2 in the brain
Kv1.1 and Kv1.2 are often associated in the same channels
in the brain [10,25]. We have previously reported a distur-
bance in the expression of Kv1.2 in the mceph/mceph hip-
pocampus [2]. To investigate if this disturbance could be
caused by an interaction between MCEPH and Kv1.2,
immunoprecipitation followed by immunoblotting was
performed on brain lysate from wild type, Kv1.1 null and
mceph/mceph mice. The monoclonal Kv1.1 and Kv1.2 anti-
bodies each precipitated both Kv1.1 and Kv1.2 in wild
type brain, verifying that correct experimental procedures
were used. As a control the same antibodies were used for
immunoprecipitation of lysate from Kv1.1 null brain. As
expected, in the Kv1.1 null lysate no Kv1.1 coprecipitated
with Kv1.2. Also, when the Kv1.1 antibody was used for
immunoprecipitation neither Kv1.1 nor Kv1.2 was
detected (Figure 4 panel A). The Kv1.1-N-terminal anti-
body precipitated Kv1.1 and Kv1.2 in wild type but also
Kv1.2 in Kv1.1 null lysate. This means that it is not specific
when used for immunoprecipitation. For mceph/mceph,
Trafficking of MCEPH Figure 3
Trafficking of MCEPH. Trafficking of MCEPH in the brain 
was determined by analyzing glycosylation pattern. Both 
EndoH and PNGaseF reduced the molecular weight with 
approximately 3 kDa (arrow). This corresponds to core glyc-
osylation. No unglycosylated MCEPH was detected.BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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immunoprecipitation was performed with anti-Kv1.2
whereas the Kv1.1-N-terminal antibody was used for
immunoblotting. With this approach it was not possible
to detect any MCEPH co-precipitating with Kv1.2 (Figure
4 panel B). This suggests that there is no persistent inter-
action between Kv1.2 and MCEPH in the brain.
On Western blots, Kv1.2 in brain appears as two bands at
60 and 88 kDa representing core and mature glycosylated
form, respectively [26]. If MCEPH binds and traps Kv1.2
in the ER, the amount of core glycosylated Kv1.2 would be
expected to increase and the mature glycosylated form
decrease. Immunoblotting was performed on lysates from
both whole brains and isolated hippocampi. The hippoc-
ampus was investigated since MCEPH is expressed prima-
rily in this brain region. Most of the Kv1.2 protein in the
hippocampus had mature glycosylation and there was
only a very small amount of core glycosylated protein. No
difference in Kv1.2 core glycosylation was seen between
wild type and mceph/mceph in neither whole brain nor
hippocampus lysate (Figure 4 panel C). When the immu-
noprecipitation and glycosylation data is combined it
Analysis of interactions between MCEPH and Kv1 subunits Figure 4
Analysis of interactions between MCEPH and Kv1 subunits. A. Immunoprecipitation was performed using a mono-
clonal Kv1.1 C-terminal antibody on brain lysate from wild type (+/+) and Kv1.1 null (-/-) mice. In wild type brain both Kv1.1 
and Kv1.2 are detected. In Kv1.1 null brain neither Kv1.1 nor Kv1.2 was detected. B. Immunoprecipitation was performed with 
the anti-Kv1.2 monoclonal antibody on brain lysate from wild type (+/+) and mceph/mceph (m/m) mice. The immunoprecipita-
tion reaction and corresponding brain lysate was loaded on SDS-PAGE. In brain lysate from mceph/mceph (BL) MCEPH was 
detected using the polyclonal Kv1.1 N-terminal antibody (arrow). However, no MCEPH band was detected in the immunopre-
cipitate from mceph/mceph (IP). C. Hippocampi were dissected and an equal amount of lysate from wild type and mceph/mceph 
was loaded on SDS-PAGE and immunoblotted with anti-Kv1.2. Only a very small fraction of the Kv1.2 was core glycosylated 
(60 kDa). There appeared to be no increase in the amount of core glycosylated Kv1.2 in mceph/mceph hippocampus compared 
to wild type. D. HEK293 cells were cotransfected with Kv1.1-DsRed and MCEPH-ZsGreen constructs. Both the 85 kDa Kv1.1-
DsRed and the 55 kDa MCEPH-ZsGreen fusion proteins were detected with immunoblotting on cell lysate using the polyclonal 
Kv1.1 N-terminal antibody (lysate). The relative levels of the two fusion proteins in this overepressing cell system cannot be 
used to quantitate MCEPH expression or stability in brain since regulation and trafficking is known to be different between 
these two systems. The lysate was immunoprecipitated with the Kv1.1 C-terminal antibody. In the precipitate, both fusion pro-
teins were detected with the Kv1.1 N-terminal antibody (IP). When the Kv1.1 C-terminal antibody was used for immunoblot-
ting only the Kv1.1-DsRed fusion protein was detected.BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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Electrophysiological recordings demonstrating the interaction between MCEPH and Kv1.2 and Kv1.3 in Xenopus oocytes Figure 5
Electrophysiological recordings demonstrating the interaction between MCEPH and Kv1.2 and Kv1.3 in Xeno-
pus oocytes. A. Currents of Kv1.2 and Kv1.3, when expressed separately and when coexpressed with MCEPH in Xenopus 
oocytes. Pulse steps from -80 to +50 mV (increment between the steps 10 mV), followed by a step to +30 to enable measure-
ments of the inactivation. B. Activation curves (peak conductance versus voltage) for Kv1.2 and Kv1.3, when expressed sepa-
rately and when coexpressed with MCEPH. Same stimulation protocols as in A. Error bars mark standard error of mean. C. 
Inactivation curves (normalized peak conductance, associated with the second pulse, versus voltage of preceding step; see 
panel A) for Kv1.2 and Kv1.3, when expressed separately and when coexpressed with MCEPH. Same stimulation protocols as 
in A. Error bars mark standard deviation.BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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appears that MCEPH does not retain Kv1.2 in the ER in
brain.
Interactions with Kv1.1 in HEK293 cells
To test if MCEPH can form multimers its ability to interact
with wild type Kv1.1 was investigated by overexpression
in cell culture. This system was chosen to allow higher
expression levels and easier detection. For this experiment
Kv1.1 and MCEPH were cloned into the vectors pZsGreen
and pDsRed2 to construct fluorescent fusion proteins.
HEK293A cells were transfected with the MCEPH-ZsGreen
and the Kv1.1-DsRed constructs together or separately
and analyzed 48 hours after transfection. The green and
the red fluorescent signals were colocalized around the
cell nucleus (data not shown). No staining was observed
on the plasma membrane. Western blot with the polyclo-
nal Kv1.1 N-terminal antibody on lysate from cotrans-
fected HEK293 cells showed bands at 55 and 85 kDa
corresponding to the MCEPH and Kv1.1 fusion proteins
(Figure 4 panel D). Corresponding bands were found in
cells transfected with single constructs which confirmed
the identity of the bands. To investigate the interaction
between MCEPH and Kv1.1, immunoprecipitation was
performed on cell lysate from cotransfected cells using the
monoclonal Kv1.1 C-terminal antibody. Immunoblotting
with the polyclonal Kv1.1 N-terminal antibody detected
the MCEPH-ZsGreen fusion protein as well as the Kv1.1-
DsRed fusion protein (Figure 3 panel D). Since the C-ter-
minal Kv1.1 antibody is specific for wild type Kv1.1 the
detected MCEPH protein was associated with the Kv1.1
protein.
Interactions with Kv1.2 and Kv1.3 in Xenopus oocytes
To further investigate the ability of MCEPH to interact
with Kv1 subunits we chose to analyze the effects of
expressing MCEPH in combination with Kv1.2 or Kv1.3 in
Xenopus laevis oocytes. Figure 5a shows the Kv1.2 and
Kv1.3 currents associated with a series of voltage steps, fol-
lowed by a step to +30 mV. Both channels show delayed
rectifier behaviour and lack fast inactivation. Kv1.3, how-
ever, shows a marked slow inactivation.
MCEPH was found to reduce the expression of both Kv1.2
and Kv1.3 in the plasma membrane. Figure 5b shows the
mean results of injecting mceph  mRNA together with
Kv1.2 or Kv1.3 mRNA (in equal amounts) given as the
effect on peak conductance versus voltage curves (i.e acti-
vation curves). As seen, the curves for Kv1.2 and Kv1.3 are
down-scaled by about 50 and 60%, respectively, without
marked changes in slope or midpoint value. The MCEPH
shift of the Kv1.3 activation curve was slightly bigger than
that of Kv1.2 (-6 mV vs. +2 mV; Table 1). The activation
time course of the currents associated with voltage steps
was negligibly affected by MCEPH, reflected in the unaf-
fected time to peak current at +50 mV for both Kv1.2 and
Kv1.3 (Table 1). Similar effects were observed for the
MCEPH effect on the slow inactivation kinetics. Mean
inactivation versus voltage curves, measured from the
peak current associated with the second pulse (Figure 5a)
are shown in Figure 5c. The MCEPH shift of the Kv1.3
inactivation curve was slightly bigger than that of Kv1.2 (-
5 mV vs. -1 mV; Table 1).
In summary, the measurements show that MCEPH has a
dominant negative effect on both Kv1.2 and Kv1.3 chan-
nel expression in Xenopus oocytes. Furthermore, the small
effects on activation and inactivation kinetics suggest that
MCEPH does not form functional channel complexes
with Kv1.2 or Kv1.3 subunits in the plasma membrane.
Heteromeric complexes involving MCEPH subunits are
expected to drastically affect channel kinetics.
Discussion
In this study we show that mceph/mceph mice express a
truncated Kv1.1, MCEPH. The MCEPH protein is
expressed in neurons throughout the brain but is trapped
Table 1: Effects of MCEPH on Kv1.2 and Kv1.3 kinetics in Xenopus oocytes. Mean midpoints of activation and inactivation curves (V1/2) 
and mean half time values (t1/2) for Kv1.2 and Kv1.3 (±SD), when expressed separately and when coexpressed with MCEPH. n is the 
number of oocytes. The activation and inactivation curves were constructed from measurements based on the stimulation protocols 
in Fig. 5. Half time value (t1/2) was measured as time to half peak current at a 50 mV pulse step (±SD).
Steady-state activation Steady-state inactivation n
V1/2 (mV) t1/2 (ms) V1/2 (mV)
Kv1.2 -24 ± 4 3 ± 1 -17 ± 7 9
Kv1.2 + MCEPH -22 ± 3 3 ± 1 -18 ± 6 10
Kv1.3 -25 ± 4 6 ± 3 -29 ± 3 7
Kv1.3 + MCEPH -31 ± 4 6 ± 3 -34 ± 4 10BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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in the ER. MCEPH is able to bind full length Kv1.1 in cell
culture and has a dominant negative effect when coex-
pressed with Kv1.2 and Kv1.3 in Xenopus oocytes. In con-
trast, in the brain MCEPH does not appear to retain Kv1.2
in the ER.
To be able to detect the truncated MCEPH protein an anti-
body against the N-terminal part of Kv1.1 was generated.
Immunoblotting on brain lysate from mceph/mceph mice
showed a band that has the same size as the predicted
MCEPH protein, approximately 30 kDa. This band is
present in all mceph/mceph brains studied but not in any
wild type or Kv1.1 null mice. Based on this we conclude
that MCEPH is expressed in the brain of the megencephaly
mouse.
Kv1.1 in the brain is a mature glycoprotein that is mostly
localized to axons and nerve terminals [6]. Truncated
Kv1.1 variants have previously been shown to be retained
in the ER in cell culture [17,20]. The draw back of these
studies is that full length Kv1.1 homomers in cell culture
is also largely retained in the ER since they are undetecta-
ble at the cell surface by immunohistochemical methods
[19] but detectable at low levels with electrophysiological
methods [27]. Lack of surface expression was seen by us
both in HEK293 cells and in the neuron-like cell line
PC12 (data not shown). The reason is a strong ER reten-
tion motif in the pore region [28]. The mceph/mceph
mouse provides an opportunity to study the trafficking of
a truncated Kv1.1 in neurons. Both EndoH and PNGaseF
treatment reduced the molecular weight of MCEPH by
approximately 3 kDa, suggesting that the protein is core
glycosylated [18]. We detected neither maturely glyco-
sylated nor unglycosylated MCEPH. The glycosylation
data suggest that MCEPH is trapped in the ER and not fur-
ther transported. This is supported by immunohistochem-
istry experiments were MCEPH immunoreactivity
surrounds the nuclei in an ER-like pattern. There is no
immunoreactivity in fibers consistent with the lack of
mature glycosylated MCEPH. The low amount of MCEPH
protein detected with immunoblotting compared to the
high levels of mRNA suggests that the MCEPH protein is
rapidly degraded. This is most likely due to ER-associated
degradation (ERAD), a quality control mechanism in the
ER that recognizes misfolded proteins [29]. These proteins
are retro-translocated to the cytosol and degraded by pro-
teasomes.
We have previously seen disturbances of staining pattern
of Kv1.2 and Kv1.3 in the mceph/mceph  hippocampus,
which was not due to transcriptional regulation [2]. Previ-
ous studies of other truncated K1.1 variants have shown
that they have a dominant negative effect in oocytes and
form oligomers with full length Kv1 subunits in cell cul-
ture. We hypothesized that MCEPH interacts with Kv1
subunits and causes the expression disturbance possibly
by retaining these subunits in the ER. Kv1.1 often forms
heterotetramers with Kv1.2 subunits in the brain [10,25].
Nevertheless, we found no evidence for a persistent inter-
action between MCEPH and Kv1.2 in the brain, suggest-
ing that there is no retention of Kv1.2 in the ER. However,
we found MCEPH to be able to oligomerize when
expressed in HEK293 cells. Moreover, electrophysiologi-
cal measurements on Xenopus  oocytes showed that
MCEPH reduces both Kv1.2 and Kv1.3 currents, suggest-
ing interaction between MCEPH and Kv1 subunits in this
cell type. This indicates that the lack of ER retention seen
for Kv1.2 in the brain is not caused by an inability of
MCEPH to form multimers
It can be assumed that lack of Kv1.1 could lead to defect
trafficking of Kv1 channels. This is not the case since the
Kv1.1 null mouse has normal expression of Kv1.2 in the
hippocampus (data not shown) and also the cerebellum
and sciatic nerve [12,30]. One possibility is that the Kv1.2
and Kv1.3 expression disturbances in mceph/mceph hip-
pocampus are related to the growth. The mceph/mceph hip-
pocampus is significantly enlarged and has an increased
amount of neurons (unpublished data). This could lead
to disturbed organization of the dendritic trees and give
rise to the abnormal expression patterns. Also, since
MCEPH contains the N-terminal T1 domain, which has
been shown to mediate beta subunit association [31,32],
it is possible that MCEPH sequesters these auxiliary subu-
nits within the ER and prevents them from forming com-
plexes with Kv1.2 and Kv1.3 in mceph/mceph mice. Beta
subunit association has been shown to promote Kv1 traf-
ficking to the cell surface as well as to cause axonal target-
ing of Kv1.2 [33].
The megencephaly mouse is not a model for any known
human disease. Still, it provides a unique tool to study
Kv1 channels in the brain. The EA1 mutation R417Stop
gives rise to a Kv1.1 protein that lacks the final 79 amino
acids in the C-terminal domain (Kv1.1∆C79). The
Kv1.1∆C79 protein and MCEPH have some similarities
but there are major differences. Both truncated proteins
have a dominant negative effect in oocytes and can assem-
ble with full length subunits in cell culture. For the
Kv1.1∆C79, change in current kinetics when coinjected
with Kv1.1 in Xenopus oocytes indicates that some chan-
nels containing truncated subunits can reach the plasma
membrane [16]. This is not seen for MCEPH which is
most likely due to the difference in length. Kv1.1∆C79
might evade the rapid degradation by cellular control
mechanisms since most of the protein remains. The trun-
cated protein can then cause more damage by retaining
subunits or by forming defect channels. This is supported
by the inheritance patterns. The R417Stop mutation is
dominant which suggests a new function for the truncatedBMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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protein, while mceph is recessive, which indicates a loss of
function.
The mechanism behind the brain growth in mceph/mceph
is still unknown. We now know that MCEPH is expressed
in the brain, but we do not know if it is MCEPH or lack of
functional Kv1.1 that is responsible for the overgrowth.
The Kv1.1 null mouse has not been reported to have an
enlarged brain which suggests that MCEPH has an effect.
However, the low levels of protein and recessive inherit-
ance indicates that the mceph mutation causes a loss of
function of Kv1.1. In line with both scenarios, it was pre-
viously shown that potassium channel dysfunction
appears to reduce apoptosis [11], which might contribute
to the overgrowth of the mceph/mceph brain.
Conclusion
For the first time we report the expression of a truncated
Kv1.1 protein in brain. This protein is trapped within ER
and has the ability to interact with Kv1 subunits. The meg-
encephaly mice, where the protein is expressed, constitute
a tool to study Kv1.1 trafficking relevant for understand-
ing epilepsy, ataxia and pathologic brain overgrowth.
Methods
Antibodies
Primary antibodies
A rabbit polyclonal antibody against the N-terminal of
Kv1.1 was generated using a synthetic peptide (CMSGE-
NADEASTAPGHPQDGSYPRQ) corresponding to amino
acids 4–27. Kv1 subunits have a high degree of homology.
The peptide for immunization was selected to have as low
similarity as possible to other Kv1 subunits. The peptide
was conjugated to KLH and injected into rabbits for pro-
duction of antiserum. The antiserum was affinity purified
against the peptide using standard procedures. The affin-
ity purified antibody was used at a 1:500 dilution for
immunoblotting and at 1:400 for immunohistochemis-
try. Monoclonal anti-Kv1.1 and anti-Kv1.2 (Upstate Bio-
technologies Inc, Waltham, MA, USA) were used for
immunoblotting at dilutions of 1:200 and 1:1000, respec-
tively.
Secondary antibodies
For immunoblotting, horseradish peroxidase coupled
swine anti-rabbit (DAKO, Glostrup, Denmark 1:2000)
and goat anti-mouse (Upstate Biotechnologies Inc
1:5000) were used. For immunohistochemistry a FITC
labeled goat anti-rabbit antibody (Sigma-Aldrich, St.
Louis, MO, USA 1:300) was used.
Experimental animals and preparation of tissues
All studies were performed in accordance with guidelines
from the Swedish National Board for Laboratory Animals.
The BALB/cByJ-mceph/mceph, BALB/cByJ-+/+ (wild type)
and C3HeB/FeJ-Kcna1tm1Tem  (Kv1.1 null) [12] mouse
strains were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). Animals were euthanized by CO2, and
the brains were removed and immersed in ice-cold phos-
phate-buffered saline (PBS) and immediately thereafter
frozen on dry ice. Serial 14 µm sections were cut in a cry-
ostat (Jung CM 3000, Leica Instruments GmbH, Nuss-
loch, Germay) at -15° and thaw-mounted on microscope
glass slides (Probe On, Fischer Scientific, Pittsburgh, PA,
USA).
For immunohistochemistry, mice were anesthetized with
isoflurane and perfused via the ascending aorta with Ca2+-
free Tyrode's solution followed by a fixative containing
4.0% paraformaldehyde and 0.4% picric acid in 0.16 M
phosphate buffer. Brains were dissected out, immersed in
ice-cold fixative for 90 min and then rinsed in 0.1 M phos-
phate buffer (pH 7.4) containing 10% sucrose, 0.01%
sodium azide and 0.02% bacitracin (Sigma-Aldrich).
Serial 14 µm sections were cut in a cryostat and mounted
on gelatin/chrome-alum coated slides.
For immunoprecipitation and immunoblotting, brains
were homogenized in RIPA buffer (150 mM NaCl, 50 mM
Tris pH 8,0, 1% NP-40, 0,1% SDS, 0,5% sodium deoxy-
cholate) with a protease inhibitor cocktail (Sigma-
Aldrich) and centrifuged at 1000 × g to pellet debris.
Plasmids
The complete Kv1.1 mRNA sequence [NCBI:
NM_010595] was PCR amplified from genomic DNA
from mceph/mceph and +/+ mice using High Fidelity Taq
polymerase (Roche Diagnostics, Basel, Switzerland). The
PCR products were TA-cloned into pCR2.1 (Invitrogen,
Carlsbad, CA, USA). The coding sequence was then sub-
cloned into the oocyte expression vector pGEM-HE (Pro-
tinac GmbH, Hamburg, Germany) using the HindIII sites
at position 823 and 2712. Correct orientation of the insert
was confirmed by restriction analysis and sequencing. Rat
cDNA for Kv1.2 and Kv1.3 in the pGEM-HE vector was
obtained from Protinac.
For expression in mammalian cells the coding sequence of
Kv1.1 was PCR amplified from genomic DNA from mceph/
mceph and +/+ mice using two different reverse primers
that removed the stop codons. The PCR products were
cloned into the vectors pDsRed2-N1 and pZsGreen-N1
(BD Biosciences Clontech Palo Alto, CA, USA) to con-
struct fluorescent fusion proteins.
Cell culture and transfection
Human embryonal kidney cells HEK293A were cultivated
in Dulbecco's modified Eagle's media (DMEM) supple-
mented with L-glutamine, 10% fetal bovine serum
(Gibco, Rockville, MD, USA) and 100 µg/ml penicillin/BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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streptomycin (Gibco) in a 37°C incubator containing 5%
CO2 humidified air. For transfection, HEK293 cells were
plated on 100 mm dishes. At 80% confluency the cells
were transfected using Lipofectamine and Plus reagent
(Invitrogen) according to the manufacturers protocol and
analyzed 48 hours after transfection. The HEK293A cells
were lysed in RIPA buffer with a protease inhibitor cock-
tail (Sigma-Aldrich). The lysate was spun 1000 × g to pel-
let debris and used for immunoprecipitation and
immunoblotting.
Immunoblotting, immunoprecipitation and glycosylation 
analysis
For immunoblotting, brain or cell lysate was diluted with
2× Laemmli loading buffer with β-mercaptoethanol and
loaded on 10% SDS-PAGE with 4% stacking gel. Proteins
were transferred to nitrocellulose membranes (Hybond-
ECL, Amersham Biosciences, Little Chalfon, UK). The
membranes were blocked in 5% milk and incubated with
the primary antibody. This was followed by incubation
with a horseradish peroxidase coupled secondary anti-
body. ECL Western blotting reagent (Amersham Bio-
sciences) was used for detection according to the
manufacturer's protocol.
For immunoprecipitation, brain lysate was incubated
with 4 µg of the indicated antibody for 2 hours on ice.
Protein-A coupled sepharose beads (Amersham Bio-
sciences) were added and the mixture was incubated for 1
hour. The beads were spun down and the supernatant was
removed. The beads were then washed three times with
RIPA buffer and once with 50 mM Tris pH 8.0. They were
then resuspended in Laemmli loading buffer and boiled
for 5 min. The supernatant was collected and analyzed by
immunoblotting.
For glycosylation analysis, brain tissue was homogenized
in a lysis buffer containing 50 mM Tris pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1% Triton X and protease inhibitors.
The homogenate was spun at 1000 × g to pellet debris. The
lysate was denatured with 0.1% SDS and 1% β-mercap-
toethanol at 100° for 5 min. Samples were incubated with
EndoH or PNGaseF according to the manufacturers proto-
col (New England Biolabs, Beverly, MA, USA) at 37° for 2
hours and analyzed with immunoblotting.
Immunohistochemistry
Brain sections were thawed quickly. Fresh frozen sections
were fixed in ice cold acetone. All slides were blocked in
PBS with 5% goat serum and 0.23% Triton-X. They were
then incubated with the primary antibody diluted in
blocking solution followed by incubation with a FITC
labeled secondary antibody. The slides were mounted
with Vectashield antifade mounting media (Vector labo-
ratories, Burlingame, CA, USA) and examined under an
Axioskop 2 microscope (Zeiss, Oberkochen, Germany).
Electrophysiology
The electrophysiological experiments comprised voltage
clamp measurements on oocytes from Xenopus laevis,
injected with mceph, Kcna2 and Kcna3 mRNA. Plasmids
with the studied genes were linearized with restriction
enzymes HindIII (Kv1.2 and Kv1.3) and Nhe1 (mceph).
The linearized DNA was purified and transcribed with the
Message Machine Kit (Ambion, Austin, TX, USA). The
mRNA product was purified and dissolved in 10 µl
ddH2O and stored at -70°C until injection in oocytes. The
mRNA injected in oocytes was diluted to one tenth of the
original concentration (2.4 mg/ml and 0.8 mg/ml, respec-
tively). The oocytes (in stage V and VI) were surgically
removed from the frog under anaesthesia, and treated
with Liberase (0.25 mg/ml) for three hours. After being
carefully rinsed the oocytes were incubated overnight in
modified Barth's solution (88 mM NaCl, 1 mM KCl, 2.4
mM NaHCO3, 0.015 mM HEPES, 0.33 mM Ca(NO3)2,
0.41 mM CaCl2, 0.82 mM MgSO4, pH adjusted to 7.5)
with added 10 µg/ml pyruvate and 10 µg/ml penicillin-
streptomycin at 10°C. They were injected with cRNA (50
nl/cell) using a Nanoject injector; Drummond Scientific,
Broomall, PA) and incubated at room temperature (20–
21°C) 16–24 hours before starting the electrophysiology
experiments (day 3 to 4 after injection).
The electrophysiological experiments were performed
with a two-electrode voltage-clamp (CA-1 amplifier,
Dagan, Minneapolis, MN). Microelectrodes were made
from borosilicate glass capillaries with a mechanical
puller and filled with 3 M KCl solution, resulting in a
resistance between 0.5 to 1.0 MΩ. The extracellular solu-
tion was composed of 88 mM NaCl, 1 mM KCl, 0.8 mM
MgCl2, 0.4 mM CaCl2, 15 mM HEPES with pH is adjusted
to 7.4. All measurements were carried out at room temper-
ature (20–22°C). The holding potential was set to -80 mV
and the interval between the test steps was 2 s (Kv1.2) and
30 s (Kv1.3). The recorded current was filtered by a low-
pass Bessel filter (5 kHz) and sampled with intervals of 2
ms (Kv1.2) and 4 ms (Kv1.3). The software used for data
collection and -analysis were pClamp5 and Clampfit 8.2
(Axon Instruments Inc., Union City, CA) and Origin 6.0
(Microcal Software Inc., Northampton, MA). To avoid dif-
ferent channel density levels due to trafficking during the
electrophysiological experiments we restricted the meas-
urements to a four-hour period.
The conductance (G) was calculated from the current (IK)
and the associated voltage step (V) by
G = IK/(V + 80 mV).   (1)BMC Neuroscience 2005, 6:65 http://www.biomedcentral.com/1471-2202/6/65
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The conductance normalized to the maximal conductance
under control conditions (Gmax CTRL) were fitted to the
Boltzmann equation
G/Gmax CTRL = 1/[1 + exp((V - V1/2)/s)],   (2)
where V1/2 is the potential at half-maximal conductance,
i.e. midpoint potential, and s is the slope. Significance of
differences was tested using the t-test.
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